Table 1.
Patient demographics and clinical characteristics.
| HIV+ Group | no HAND | HAND | p* | |
|---|---|---|---|---|
| Number of patients (%) | 103 | 73 (71%) | 30 (29%) | |
| Age at Baseline (years) Median (IQR)# |
43 (38–50) | 43 (36–49) | 44 (40–55) | 0.12 |
| HCV positive (%) | 29% | 27% | 30% | 0.66 |
| HIV RNA plasma (log10 cp/ml) Median (IQR) |
1.6 (1.6–2.4) | 1.6 (1.6–2.6) | 1.6 (1.6–2) | 0.87 |
| Undetectable HIV RNA (%) | 65% | 65% | 64% | 0.85 |
| Nadir CD4 count (cells/μL) Median (IQR) |
227 (76–350) | 216 (78–372) | 238 (58–350) | 0.74 |
| CD4+ cell count (cells/μL) Median (IQR) | 495 (358–747) | 480 (372–729) | 504 (351-765) | 0.83 |
| CD8+ cell count (cells/μL) Median (IQR) |
807 (549–1089) | 765 (543–1023) | 1045 (732–1399) | 0.02 |
| Duration of HIV infection (years) Median (IQR) | 14.5 (5–19) | 13.5 (5–18) | 15.5 (7.5–20) | 0.49 |
| On antiretroviral therapy (%) | 77% | 75% | 77% | 0.47 |
| Years of current treatment Median (IQR) | 2 (1–2.8) | 1.45 (1–2.35) | 2 (1.5–3) | 0.1 |
*Wilcoxon Mann Whitney test comparison between HAND and no HAND patients. Statistically significant p value ≤0.05 is written in bold.
#IQR: Interquartile range.